PALAVRAS EM INGLÊS RELACIONADAS COM «FACTOR VIII»
factor VIII
high
factor
viii
inhibitor
products
medication
dosing
elevated
administration
deficiency
essential
blood
clotting
protein
also
known
anti
hemophilic
humans
encoded
gene
defects
this
results
hemophilia
medscape
reference
hemostatic
system
consisting
their
content
plays
crucial
role
human
survival
procoagulant
component
genetics
provides
instructions
making
factors
group
related
proteins
assay
medlineplus
medical
encyclopedia
test
measures
activity
substances
involved
homo
sapiens
encodes
intrinsic
pathway
journal
life
cycle
view
located
long
chromosome
spans
over
such
largest
genes
haemophilia
10 LIVROS EM INGLÊS RELACIONADOS COM «FACTOR VIII»
Descubra o uso de
factor VIII na seguinte seleção bibliográfica. Livros relacionados com
factor VIII e pequenos extratos deles para contextualizar o seu uso na literatura.
1
Factor VIII - von WIllebrand
Factor
In volume I (Subtitled: Biochemical, methodological and functional aspects), the purification and structure/function relationships of VIII and vWf are extensively reviewed with the relevance of advances in these areas to improved ...
M. J. Seghatchian, G. F. Savidge, 1989
2
Disorders of Thrombosis and Hemostasis: Clinical and ...
One BU is defined as the amount of anti-factor VIII necessary to neutralize 50% of
factor VIII in 1 mL of pooled normal plasma after incubation for 2 hours at 37°C.
The Bethesda assay can be adapted for the determination of the titer of inhibitor ...
3
Clinical Laboratory Medicine
LABORATORY RESULTS IN HEMOPHILIA A PT APTT Bleeding Time Platelet
Count Factor VIII:C Assay Normal Abnormal* Normal Normal Abnormal APTT,
activated partial thromboplastin time. PT, prothrombin time The APTT may be ...
Kenneth D. McClatchey, 2002
4
Hematology: Clinical Principles and Applications
Because factor VIII has a half-life of 8 to 12 hours, infusions are required at least
twice per day. Many hemophiliacs maintain themselves on a steady prophylactic
dose designed to keep the factor VIII level greater than 1%.63 Although initially ...
5
Wintrobe's Clinical Hematology
Factor VIII, or antihemophilic factor, is a nonenzymatic procofac- tor that circulates
in plasma in complex with the large multimeric protein vWF. Initially, factor VIII
and vWF were thought to be a single entity, and early reports on factor VIII were ...
6
Blood Banking and Transfusion Medicine: Basic Principles & ...
In the United States, current use of cryoprecipitate is almost exclusively limited to
the replacement of fibrinogen in hypofibrinogenemic patients. However, prior to
the advent of purified factor VIII, cryoprecipitate was the mainstay of treatment for
...
Christopher D. Hillyer, 2007
7
Recombinant Protein Drugs
FVIII Figure 4. Derivation of factor VIII and von Willebrand factor coexpressing
CHO cells used for the manufacture of recombinant factor IX. Adapted from
Kaufman [45] with permission. Plasmids encoding DHFR and factor VIII were
transfected ...
8
Textbook of Pediatric Emergency Medicine
When plasma is frozen and then slowly thawed, the precipitate that forms
contains enriched factor VIII coagulant activity, VWF, fibrinogen, and factor XIII.
However, like fresh-frozen plasma, the actual amount of these clotting factors in a
single ...
Gary R. Fleisher, Stephen Ludwig, 2010
9
Hemostasis and Thrombosis: Basic Principles and Clinical ...
Factor VIII circulates in plasma in an inactive form that is proteolytically cleaved
by factor Xa and/or thrombin to yield activated factor VIIIa. Factor VIIIa serves as a
cofactor for factor IXa-mediated proteolytic activation of factor X. Subsequently, ...
10
Critical Care Obstetrics
The second treatment option consists of factor VIII and vWF replacement. Fresh
frozen plasma contains both factors, but large volumes are required to stop or
prevent bleeding. Cryoprecipitate contains 5–10 times higher concentration of
both ...
George R. Saade, Michael R. Foley, Jeffrey P. Phelan, 2010
10 NOTÍCIAS NAS QUAIS SE INCLUI O TERMO «FACTOR VIII»
Conheça de que se fala nos meios de comunicação nacionais e internacionais e como se utiliza o termo
factor VIII no contexto das seguintes notícias.
Xenetic Biosciences Completes $3000000 Bridge Note Financing
... series of polysialylated blood coagulation factors, including a next generation Factor VIII. This collaboration relies on the PolyXen technology ... «GlobeNewswire, jul 15»
Moves to protect availability of haemophilia treatments
In changes to take effect from 1 September, PHARMAC is moving to have a preferred brand of recombinant Factor VIII, while also maintaining ... «PharmiWeb.com, jul 15»
Competition Rising for Baxalta
Baxalta should gain approval for twice-weekly Factor VIII protein BAX 855 in late 2015, but more convenient (perhaps once-monthly) treatments ... «Morningstar.com, jul 15»
Baxalta: A Spin-Off That Could Be Revalued Up To 50% Higher
... generic version of Baxalta's Advate, many companies will simply not be able to replicate a large, relatively unstable protein that is Factor VIII. «Seeking Alpha, jul 15»
EXCLUSIVE: I saw all three of my brothers die after they were given …
He became infected with HIV, Hepatitis C, Hepatitis B, Cytomegalovirus (CMV) and the human herpes virus after receiving Factor VIII blood ... «Express.co.uk, jul 15»
ALJ Lord sets 16-month target date in Certain Recombinant Factor …
On May 26, 2015, ALJ Dee Lord issued Order No. 3 in Certain Recombinant Factor VIII Products (Inv. No. 337-TA-956). By way of background, ... «Lexology, jul 15»
Bayer Files Hemophilia A Drug Marketing Application in Japan
BAY 94-9027 is a site-specific PEGylated recombinant factor VIII. BAY 94-9027, currently in phase III, is being developed for patients suffering ... «Zacks.com, jul 15»
Baxalta Spins Off from Baxter
... Complex (Human)] with new offerings that include BAX 855, an extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A to ... «Genetic Engineering & Biotechnology News, jul 15»
Bayer Yakuhin seeks Japanese marketing nod for recombinant …
BAY 81-8973 is a full-length recombinant factor VIII which has shown clinical benefit of efficacy when used for prophylaxis twice or three times ... «pharmabiz.com, jun 15»
BRIEF-Bayer submits application for recombinant factor compound …
Bayer submits an application for market authorization of recombinant factor VIII product as a treatment of hemophilia a in Japan Further ... «Reuters, jun 15»
